Fresh From the Bench: Latest Federal Circuit Court Cases
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Valeant Pharmaceuticals North America LLC v. Mylan Pharmaceuticals Inc., Appeal No. 2019-2402 (Fed. Cir. Nov. 5, 2020)
In our Case of the Week, the Federal Circuit addressed a lingering question about venue following the Supreme Court’s decision in TC Heartland LLC v. Kraft Foods Grp. Brands LLC, 137 S. Ct. 1514 (2017). Specifically, the Court answered the question about how the patent venue statute, 28 U.S.C. § 1400, applies to cases brought under the Hatch-Waxman Act.
Read More.
By: Nika F. Aldrich
ALSO THIS WEEK
Chevron U.S.A. Inc. v. University of Wyoming Research Corporation, Appeal No. 2019-1530 (Fed. Cir. Nov. 4 2020)
In this appeal from an interference proceeding before the Patent Trial and Appeal Board, the Court affirmed the Board’s assignment of priority to the University of Wyoming. The Court affirmed the Board’s claim construction of the terms “gradually and continuously,” holding the Board properly relied on the definitions of those terms explicitly contained in Wyoming’s claims. Since Chevron’s earliest corroborated conception coupled with diligence date was after the priority date of Wyoming’s relevant applications, the Court affirmed the Board’s finding of Wyoming as the senior party and affirmed the Board’s judgement of interference in Wyoming’s favor. Judge Newman dissented, opining that the Board “erred at the threshold” by initiating the interference proceeding because the patents at issue claimed different inventions.
The opinion can be found here.
By: Bazsi Takacs
Edited by: Scott D. Eads and Nika Aldrich, Schwabe Williamson & Wyatt
Contributor: Bazsi Takacs
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…